Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

A proactive strategy that promotes U.S. pharmaceutical manufacturing is a crucial pillar within a resilient and diversified ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Alliance Pharmaceuticals, a U.S. based pharmaceutical solutions provider, announced its new partnership with TrueMed, an AI-based anti-counterfeit detection company. The partnership was formed with ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...

Marcel Botha discusses whether AI can truly be used to replace laid off human workers at FDA.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...